GPR37 processing in neurodegeneration: a potential marker for Parkinson’s Disease progression rate
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
GPR37 processing in neurodegeneration: a potential marker for Parkinson’s Disease progression rate ; volume:10 ; number:1 ; day:10 ; month:9 ; year:2024 ; pages:1-11 ; date:12.2024
npj Parkinson's Disease ; 10, Heft 1 (10.9.2024), 1-11, 12.2024
- Creator
-
Argerich, Josep
Garma, Leonardo D.
López-Cano, Marc
Álvarez-Montoya, Paula
Gómez-Acero, Laura
Fernández-Dueñas, Víctor
Muñoz-Manchado, Ana B.
Aso, Ester
Boxer, Adam
Andres-Benito, Pol
Svenningsson, Per
Ciruela, Francisco
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41531-024-00788-x
- URN
-
urn:nbn:de:101:1-2411242111288.301112215620
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:29 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Argerich, Josep
- Garma, Leonardo D.
- López-Cano, Marc
- Álvarez-Montoya, Paula
- Gómez-Acero, Laura
- Fernández-Dueñas, Víctor
- Muñoz-Manchado, Ana B.
- Aso, Ester
- Boxer, Adam
- Andres-Benito, Pol
- Svenningsson, Per
- Ciruela, Francisco
- SpringerLink (Online service)
Other Objects (12)
Association of retinal neurodegeneration with the progression of cognitive decline in Parkinson’s disease
Does the MDS-UPDRS provide the precision to assess progression in early Parkinson’s disease? Learnings from the Parkinson’s progression marker initiative cohort
Prevention of progression in Parkinson’s disease
Neurodegeneration and Neuroinflammation in Parkinson’s Disease: a Self-Sustained Loop
Molekulare Mechanismen der Neurodegeneration bei Morbus Parkinson
Step Length Is a Promising Progression Marker in Parkinson's Disease
Quality of life in Parkinson’s disease patients: progression markers of mild to moderate stages
Two distinct trajectories of clinical and neurodegeneration events in Parkinson’s disease
Lipid and immune abnormalities causing age-dependent neurodegeneration and Parkinson’s disease
Purinergic Signalling in Parkinson’s Disease: A Multi-target System to Combat Neurodegeneration
Altered event processing in persons with Parkinson’s disease
Reward processing in Parkinson's disease
Association of retinal neurodegeneration with the progression of cognitive decline in Parkinson’s disease
Does the MDS-UPDRS provide the precision to assess progression in early Parkinson’s disease? Learnings from the Parkinson’s progression marker initiative cohort
Prevention of progression in Parkinson’s disease
Neurodegeneration and Neuroinflammation in Parkinson’s Disease: a Self-Sustained Loop
Molekulare Mechanismen der Neurodegeneration bei Morbus Parkinson
Step Length Is a Promising Progression Marker in Parkinson's Disease
Quality of life in Parkinson’s disease patients: progression markers of mild to moderate stages
Two distinct trajectories of clinical and neurodegeneration events in Parkinson’s disease
Lipid and immune abnormalities causing age-dependent neurodegeneration and Parkinson’s disease
Purinergic Signalling in Parkinson’s Disease: A Multi-target System to Combat Neurodegeneration
Altered event processing in persons with Parkinson’s disease
Reward processing in Parkinson's disease
Association of retinal neurodegeneration with the progression of cognitive decline in Parkinson’s disease
Does the MDS-UPDRS provide the precision to assess progression in early Parkinson’s disease? Learnings from the Parkinson’s progression marker initiative cohort
Prevention of progression in Parkinson’s disease
Neurodegeneration and Neuroinflammation in Parkinson’s Disease: a Self-Sustained Loop
Molekulare Mechanismen der Neurodegeneration bei Morbus Parkinson
Step Length Is a Promising Progression Marker in Parkinson's Disease
Quality of life in Parkinson’s disease patients: progression markers of mild to moderate stages
Two distinct trajectories of clinical and neurodegeneration events in Parkinson’s disease
Lipid and immune abnormalities causing age-dependent neurodegeneration and Parkinson’s disease
Purinergic Signalling in Parkinson’s Disease: A Multi-target System to Combat Neurodegeneration
Altered event processing in persons with Parkinson’s disease